Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 10, 2000 - Issue 9
Submit an article Journal homepage
57
Views
14
CrossRef citations to date
0
Altmetric
Review

PDE4 inhibitors: sustained patenting activity as leading drugs near the market

Peter Norman 18 Pink Lane, Burnham, Bucks SL1 8JW, UK. [email protected]
Pages 1415-1427 | Published online: 25 Feb 2005

Bibliography

  • NORMAN P: PDE4 inhibitors 1999. Exp. Opin. Ther. (1999) 9:1101–1118.
  • ••Previous review in this series.
  • DYKE HJ, MONTANA JG: The therapeutic potential of4 inhibitors. Exp. Opin. Invest. Drugs (1999) 8:1301–1325.
  • ••Useful review that considers various therapeutic opportuni-ties and current developments.
  • NORMAN P: COPD, new developments & therapeutic. Drug News Perspect. (1998) 11:431–437
  • •Meeting report that highlights the potential of new therapeu-tics such as PDE4 inhibitors.
  • SMITHKLINE BEECHAM PLC: New study shows ariflo, Beecham's investigational PDE4 inhibitor, improved pulmonary function in chronic obstructive pulmonary disease. Press Release (12 October 1999).
  • ••The most significant clinical data yet released on cilomilast.
  • SOUNESS JE, FOSTER M: Potential of phosphodiesterase W inhibitors in the treatment of rheumatoid arthritis. IDrugs (1998) 1:541–553.
  • •Good review of this potential use for PDE4 inhibitors.
  • TORPHY TJ: Phosphodiesterase isozymes. Molecular for novel anti-asthma agents. Am. J Resp. Grit. Care Med. (1998) 157:351–370.
  • ••Key review from the field leader.
  • GIEMBYCZ MA: Phosphodiesterase 4 inhibitors and the of asthma: where are we now and where do we go from here? Drugs (2000) 59(2):193–212.
  • ••Unbiased perspective on recent developments and thepotential of PDE4 inhibitors.
  • INFLAZYME PHARMACEUTICALS LTD.: In flazyme announces selection of phosphodiesterase-4 inhibitor without potential for emesis - data to be presented at chase H&Q healthcare conference. Press Release (10 January, 2000).
  • COMPTON C, DUGGAN M, CEDAR E et al.: Safety of ariflo in a 12-month study of patients with asthma. Am. J Respir. Grit. Care Med (2000) 1 61 :A200.
  • •Long-term tolerability of cilomilast.
  • COMPTON C, DUGGAN M, CEDAR E et al.: Ariflo efficacy a 12-month study of patients with asthma. Am. J Respir. Grit. Care Med (2000) 1 61 :A505
  • •Long-term efficacy of cilomilast.
  • ZUSSMAN BD, KELLY J, MURDOCH R et al.: Ariflo, a novel &selective oral PDE4 inhibitor, has a favorable metabolic profile with low potential for drug-drug interactions. Am. J. Respir. Grit. Care Med. (2000) 161:A492
  • ZUSSMAN BD, KELLY J, MURDOCH R et al.: Ariflo, a novel &selective oral PDE4 inhibitor, has linear pharma-cokinetics and high bioavailability. Am. J Respir. Grit. Care Med. (2000) 1 61 :A574.
  • KELLY J, ZUSSMAN B, WEBBER D et al.: Ariflo (SB-207499), an orally active, novel and selective PDE4 inhibitor, had no effect on the steady state pharma-cokinetics of digoxin (375mcg od) in healthy volunteers. Am. J. Respir. Grit. Care Med. (2000) 161:A573.
  • MURDOCH RD, KELLY J, CLARK DJ et al.: An orally active, novel and selective PDE4 inhibitor, does not potentiate the anti-coagulatory effect of warfarin in healthy male volunteers. Am. J. Respir. Grit. Care Med. (2000) 161 :A572.
  • TIMMER W, LECLERC V, BIRRAUX G et al.: Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks. Am. J. Respir. Grit. Care Med (2000) 161:A505.
  • •Initial clinical efficacy data on roflumilast.
  • MURDOCH RD, COWLEY H, UPWARD J eta].: The safety tolerability of ariflo (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Am. J. Respir. Grit. Care Med. (1998) 157:A409.
  • •Study indicating that cilomilast can cause emesis.
  • NELL H, LEICHTL S, RATHGEB F et al.: Acuteanti-inflammatory effect of the novel phosphodies-terase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Am. J Respir. Grit. Care Med. (2000) 1 61 :A200.
  • STURTON RG, BUTT NM, PALFAI SP et al. Molecular andcellular profile of the structurally novel phosphodies-terase (PDE) 4 Inhibitor, BAY19-8004. Am.J. Respir. Grit. Care Med. (2000) 161:A200
  • •Characterisation of a novel PDE4 inhibitor.
  • FITZGERALD MF, BRIGGS BA, THOMPSON AM eta]. Theevaluation of a selective phosphodiesterase (PDE) 4 inhibitor, Bay 19–8004, in guinea-pig antigen challenge and ferret emesis models. Am. J. Respir. Grit. Care Med. (2000) 161:A201
  • FITCH N, FREEMAN MS, STURTON RG eta].: The effect ofan oral phosphodiesterase (PDE) 4 inhibitor bay 19–8004 in primate asthma models. Am. J. Respir. Grit. Care Med. (2000) 161 :A201
  • •Indicative of the high oral potency of this novel PDE4 inhibitor.
  • SPICER D, FITZGERALD MF, CLARK E eta].: Efficacy of the selective phosphodiesterase (PDE) 4 Inhibitor, bay 19–8004, in a rat model of neutrophilic lung inflamma-tion. Am. J. Respir. Grit. Care Med. (2000) 161:A578
  • JENSEN L, GRISWOLD DE, AAES H et al.: Cipamfylline - a promising drug for topical treatment of atopic dermatitis. Mediators Inflamm. (1999) 8 (Supp1.1) :11–10.
  • CHIROSCIENCE LTD.: Drug development pipeline: D-4396/D-4418. Press Release (12 May, 1999).
  • MCGARRY DG, REGAN JR, VOLZ FA et al: Benzofuran based PDE4 inhibitors. Bioorg. Med. Chem. 7: 1131-1139 (1999).
  • PASCAL Y, ANDRIANJARA CR, AUCLAIR E et al: Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro41,4]diazepino[6,7,1-hi]-indoles: novel PDE4 inhibitors. Bioorg. Med. Chem. Lett. (2000) 10(1):35–38.
  • •Preliminary SAR on this novel structural class.
  • PERRIER H, BAYLY C, LALIBERTE F et al: Substituted furans as inhibitors of the PDE4 enzyme. Bioorg. Med. Chem. Lett. (1999) 9(3):323–326.
  • WANG P, WU P, OHLETH KM et al: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expres-sion in human monocytes and neutrophils. MoL Pharmacol. (1999) 56:170–174.
  • FUHRMANN M, JAHN HU, SEYBOLD J et af: Identificationand function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am. J. Resp. Mol Biol. (1999) 20:292–302.
  • MANNING CD, BURMAN M, CHRISTENSEN SB et al: Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br]. Pharmacol (1999) 128 (7):1393–1398.
  • ••Key study highlighting the target isozyme in monocytes.
  • YARWOOD SJ, STEELE MR, SCOTLAND G et al: The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol. Chem. (1999) 274(20:14909–14917.
  • ALLEN RA, MERRIMAN MW, PERRY MJ, OWENS RJ: Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors. Biochem. Pharmacol. (1999) 57:1375–1382.
  • •The modern approach to screening PDE4 inhibitors.
  • HERSPERGER R, BRAY-FRENCH K, MAZZONI L, MULLER T: Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase Type 4D inhibitors. J. Med. Chem. (2000) 43 (0675–682.
  • HERMAN SB, JUILFS DM, FAUMAN EB, JUNEAU P, MENETSKI JP: Analysis of a mutation in phosphodies-terase Type 4 that alters both inhibitor activity and nucleotide selectivity. Mol. Pharmacol. (2000) 57 (5):991–999.
  • XU RX, HASSELL AM, VANDERWALL D et al: Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (2000) 288 (5472) :1822–1825.
  • •The structural basis for inhibitor activity and design.
  • LALIBERTE F, HAN Y, GOVINDARAJAN A et al: Confor- difference between PDE4 apoenzyme and. Biochemistry (2000) 39 (20:6449–6458.
  • •Molecular rationalisation of the distinction between the low and high affinity rolipram binding sites.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.